TI
ABCL icon

Trexquant Investment’s AbCellera Biologics ABCL Stock Holding History

Trexquant Investment’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-272,158
Closed -$1.25M – 1373
2023
Q3 		$1.25M Buy
272,158
+223,430
+459% +$1.36M 0.03% 663
2023
Q2 		$315K Buy
+48,728
New +$333K 0.01% 1180
2023
Q1 		– Sell
-97,842
Closed -$991K – 1394
2022
Q4 		$991K Buy
+97,842
New +$1.13M 0.03% 647
2022
Q3 		– Sell
-173,864
Closed -$1.85M – 1308
2022
Q2 		$1.85M Sell
173,864
-57,008
-25% -$483K 0.08% 292
2022
Q1 		$2.25M Buy
230,872
+173,765
+304% +$1.65M 0.11% 238
2021
Q4 		$817K Buy
+57,107
New +$867K 0.05% 457
2021
Q3 		– Sell
-11,102
Closed -$244K – 1079
2021
Q2 		$244K Buy
+11,102
New +$306K 0.02% 807

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Trexquant Investment's ABCL Position: Q4 2023 in Review

Trexquant Investment sold out of AbCellera Biologics (ABCL) in Q4 2023, closing a stake of 272,158 shares — an estimated $1.25M sold.

Trexquant Investment first reported a position in ABCL in Q2 2021 and held it in 7 quarters. The position peaked at $2.25M in Q1 2022. 142 funds tracked by Wall St. Rank hold ABCL as of Q4 2023.

  • Trexquant Investment reported no remaining AbCellera Biologics position as of Q4 2023 after selling out during the quarter.
  • Trexquant Investment sold 272,158 AbCellera Biologics shares in Q4 2023, an estimated $1.25M.
  • Trexquant Investment first reported a position in AbCellera Biologics in Q2 2021 and held it in 7 quarters.
  • Trexquant Investment's AbCellera Biologics position peaked at $2.25M in Q1 2022.
  • 142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2023.

Based on Trexquant Investment's 13F filing for Q4 2023, filed 9 Feb 2024.